Your Super just launched in the United States after years of success in Europe. Alyssa Julya Smith sits down with co-founders Michael Kuech and Kristel de Groot to learn all about the inspiration behind their superfood business. The co-founders explain that the idea was launched after Kuech was diagnosed with cancer at age 24. After this nerve-wracking diagnosis, Michael and his co-founder, Kristel de Groot, realized how powerful it is to fuel your body with a healthy, whole food diet. Alongside orthomolecular nutritionists, the duo started Your Super and developed seven easy-to-use superfood mixes comprised of 100% organic, nutrient-dense whole foods. The explained that the mixes consist of easy powders that you can add to lots of different foods, making it easy for everyone to get the rich vitamins, nutrients and minerals they need each day.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More